Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
October 13 2023 - 6:00AM
Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today
announced that the Company will present a poster at the
American Society of Nephrology’s upcoming Kidney Week 2023 Annual
Meeting taking place in Philadelphia, PA from November 2-5, 2023.
The poster will highlight new data from Eledon’s ongoing open-label
Phase 1b trial evaluating tegoprubart for the prevention of
rejection in kidney transplantation.
Details on the poster presentations are below:
Title: Tegoprubart for the prevention of
rejection in kidney transplant: update of emerging data from an
ongoing trialPresenter: Steve Perrin, Ph.D.,
President and Chief Scientific Officer, Eledon
PharmaceuticalsPoster
Number: TH-PO835Session Title:
Transplantation: Clinical - I [PO2102-1] Session Date
and Time: November 2, 2023 from 10:00 AM to 12:00 PM
EDT
Following the presentation, a copy of the poster
can be found on the Investor section of the Company’s website
at https://ir.eledon.com/events-and-presentations/presentations.
About Eledon Pharmaceuticals and Tegoprubart
(formerly AT-1501)
Eledon Pharmaceuticals is a clinical stage
biotechnology company with immunology expertise that is developing
therapies to protect and prevent rejection of transplanted organs,
as well as to treat amyotrophic lateral sclerosis (ALS). The
Company’s lead compound in development is tegoprubart, an
anti-CD40L antibody with high affinity for CD40 Ligand (also called
“CD154”), a well-validated biological target with broad therapeutic
potential. Eledon is headquartered in Irvine, California. For
more information, please visit the company’s website
at www.eledon.com.
Follow Eledon Pharmaceuticals on social
media: LinkedIn; Twitter
Investor Contact:
Stephen JasperGilmartin Group(858) 525
2047stephen@gilmartinir.com
Media Contact:
Jenna UrbanBerry & Company Public Relations(212) 253
8881jurban@berrypr.com
Source: Eledon Pharmaceuticals
Eledon Pharmaceuticals (NASDAQ:ELDN)
Historical Stock Chart
From May 2024 to Jun 2024
Eledon Pharmaceuticals (NASDAQ:ELDN)
Historical Stock Chart
From Jun 2023 to Jun 2024